NasdaqGS:ATRI

Stock Analysis Report

Executive Summary

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide.

Snowflake

Fundamentals

Flawless balance sheet with acceptable track record.

Risks

  • Atrion is not covered by any analysts.

Similar Companies

Share Price & News

How has Atrion's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.9%

NasdaqGS:ATRI

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

26.8%

NasdaqGS:ATRI

8.7%

US Medical Equipment

1.7%

US Market

ATRI outperformed the Medical Equipment industry which returned 8.7% over the past year.

ATRI outperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

ATRIIndustryMarket
7 Day3.9%-1.2%1.2%
30 Day7.3%1.4%4.9%
90 Day-8.3%4.8%3.7%
1 Year27.7%26.8%9.6%8.7%3.9%1.7%
3 Year92.8%88.5%70.8%65.5%47.2%37.7%
5 Year162.7%152.2%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is Atrion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Atrion undervalued based on future cash flows and its price relative to the stock market?

40.95x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Atrion's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Atrion's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Atrion is good value based on earnings compared to the US Medical Equipment industry average.

Atrion is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Atrion, we can't assess if its growth is good value.


Price Based on Value of Assets

Atrion is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Atrion expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

-2.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Atrion is high growth as no revenue estimate data is available.

Atrion's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

Unable to compare Atrion's revenue growth to the United States of America market average as no estimate data is available.

Atrion's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Atrion's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Atrion will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Atrion performed over the past 5 years?

6.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Atrion's year on year earnings growth rate has been positive over the past 5 years.

Atrion's 1-year earnings growth exceeds its 5-year average (6.4% vs 6.3%)

Atrion's earnings growth has not exceeded the US Medical Equipment industry average in the past year (6.4% vs 28.9%).


Return on Equity

Atrion has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Atrion used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Atrion's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Atrion's financial position?


Financial Position Analysis

Atrion is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Atrion's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Atrion has no debt.

Atrion has not taken on any debt in the past 5 years.

Atrion has no debt, it does not need to be covered by operating cash flow.

Atrion has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Atrion has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Atrion's current dividend yield, its reliability and sustainability?

0.78%

Current Dividend Yield


Dividend Yield and Payments Analysis

Atrion's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.45%).

Atrion's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).

Atrion is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Atrion is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Atrion's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Atrion's salary, the management and board of directors tenure and is there insider trading?

21.7yrs

Average board tenure


CEO

David Battat (49yo)

8.3yrs

Tenure

US$1,543,530

Compensation

Mr. David A. Battat has been the Chief Executive Officer of ATRION Corp. since May 26, 2011 and has been its President since May 2011. Mr. Battat has been the President of Halkey-Roberts Corporation, a sub ...


CEO Compensation Analysis

David's remuneration is lower than average for companies of similar size in United States of America.

David's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

21.7yrs

Average Tenure

70yo

Average Age

The average tenure for the Atrion board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$17,15728 May 19
Ronald Spaulding
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares19
Max PriceUS$903.00
SellUS$163,44328 May 19
Ronald Spaulding
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares181
Max PriceUS$903.00
SellUS$1,536,13229 Nov 18
Jeffery Strickland
EntityIndividual
Role
Chief Financial Officer
VP, CFO
Shares2,000
Max PriceUS$771.00

Ownership Breakdown


Management Team

  • Emile Battat (81yo)

    Executive Chairman

    • Tenure: 21.7yrs
    • Compensation: US$665.27k
  • Jeffery Strickland (60yo)

    VP, CFO

    • Tenure: 22.6yrs
    • Compensation: US$953.00k
  • David Battat (49yo)

    President & CEO

    • Tenure: 8.3yrs
    • Compensation: US$1.54m

Board Members

  • Emile Battat (81yo)

    Executive Chairman

    • Tenure: 21.7yrs
    • Compensation: US$665.27k
  • Hugh Morgan (90yo)

    Independent Director

    • Tenure: 31.7yrs
    • Compensation: US$132.00k
  • John Stupp (69yo)

    Independent Director

    • Tenure: 34.7yrs
    • Compensation: US$140.22k
  • Nicky Spaulding (55yo)

    Independent Director

    • Tenure: 13.6yrs
    • Compensation: US$130.00k
  • Preston Athey (70yo)

    Independent Director

    • Tenure: 2.5yrs
    • Compensation: US$126.00k

Company Information

Atrion Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atrion Corporation
  • Ticker: ATRI
  • Exchange: NasdaqGS
  • Founded: 1944
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$1.478b
  • Shares outstanding: 1.85m
  • Website: https://www.atrioncorp.com

Number of Employees


Location

  • Atrion Corporation
  • One Allentown Parkway
  • Allen
  • Texas
  • 75002
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATRINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 1969

Biography

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and r ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 23:32
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.